1
Intersect ENT
1 in 8 Adults
25 work days lost per year
Top 10 Most Costly Condition
for US Employers
2
Innovation Solutions, Clinically Proven
FAMILY
3
Portfolio Extending Across
CS Indications and Care Settings
Frontal
Ethmoid
Maxillary
4
Large Patient Population and Market
Addressing CS Across the Continuum of Care
* Company estimates.
5
Commitment to Evidence-Based Innovation
FAMILY
6
FAMILY
Improving Surgical Outcomes
7
PROPEL and PROPEL Mini
Surgical Products to Improve Outcomes
ETHMOID SINUS
8
PROPEL and PROPEL Mini
Clinically Proven Outcomes
Meta-analysis: Han JK, Marple BF, Smith TL et al. Int Forum Allergy Rhinol, Vol. 2, No. 4, July/August 2012 9
PROPEL Contour
Expanding Addressable Markets
OVERVIEW
• Designed for Patients in Surgical or Office Setting
of Care
• Enhances Physician Choice: Smaller Size, Unique
Hourglass Shape, Flexible Applicator FRONTAL AND
MAXILLARY SINUSES
10
PROPEL Contour
Clinically Proven Outcomes
Luong A, et al., JAMA Otolaryngology–Head & Neck Surgery, Published online November 2, 2017. *Judged by an independent reviewer.
11
** Judged by clinical investigators. The p-values for the secondary endpoints were adjusted for multiplicity.
PROPEL FAMILY
Continuing Commercial Traction
1 in 3 ENTs
~ 50% of Accounts
• PROPEL Contour Roll-out
12
PROPEL Family
Reimbursement and Value Proposition in Place
REIMBURSEMENT IN PLACE
Covered through Hospital Facility Fee
Drugs
Reimbursement
Repair of
Turbinate COST EFFECTIVENESS STUDY1
Lateralization Placement of PROPEL following FESS
“is a cost-effective intervention
Surgical for preventing a postoperative
Adhesion Lysis intervention within 60 days
after surgery.”
Polypectomy
14
SINUVA
Office Treatment for Recurrent CRS/Polyps
OVERVIEW
• Designed for Patients Who Have Had Prior Surgery
• Dilates Obstructed Cavity
• Delivers~4x Steroid (vs. PROPEL) Over 90 Days
• 100% Patient Compliance ETHMOID SINUS
15
SINUVA
Clinically Proven Outcomes
• Data on file, Intersect ENT. RESOLVE II CR-00014 Rev. 1.0 January 2018 16
SINUVA
Reduction in Polyps and Sinus Obstruction
ENDOSCOPIC OUTCOMES
-5
-5%
Change from Baseline
-0.5
-10
-10%
-1 -15
-15%
-20
-20%
-1.5
* * -25%
-25
*
*
-2 * -30%
-30 * *
*
Treatment Control
• Data on file, Intersect ENT. RESOLVE II CR-00014 Rev. 1.0 January 2018. Grading by Clinical Investigators. 17
SINUVA
Reimbursement
Reimbursement Healthcare Economics
$0.40
$0.20
$-
Current Environment "New" Environment
PROCEDURE CODE(S)
• Budget Impact Model1 Presented at
Procedure Reimbursement via ISPOR2 May, 2018
Existing CPT Procedure Codes, • Analysis Modelled 23%-35% Cost
as per Physician Work Provided Savings Scenarios
(1) Steroid-Eluting Sinus Implant Versus Revision Surgery for Patients with Recurrent Chronic Rhinosinusitis with Nasal Polyps
(CRSwNP): An Economic Model, Frank R. Ernst, PharmD, MS1; Ryan J. Imhoff, MS1; Adam DeConde, MD2; Peter Manes, MD3
1. CTI Clinical Trial and Consulting Services, Inc., Covington, KY USA; 2. University of California-San Diego, San Diego, CA USA;
3. Yale School of Medicine, New Haven, CT USA
(2) International Society For Pharmacoeconomics and Outcomes Research 18
SINUVA
Elements for Success
PAYOR COVERAGE
PHYSICIAN & PATIENT
Strong National Coverage;
EXPERIENCE
Emerging Positive Payment
Positive Clinical Outcomes
History
RX
MARKET ACCESS
SALES FORCE
Reimbursement “Hub” facilitates
Expanding Team +30%;
coverage assessment; Specialty
Complementing with Field
Pharmacy and Specialty
Reimbursement Team
Distributor Access
19
ASCEND Drug Coated Balloon
Emerging Pipeline Product
MARKET OPPORTUNITY
ASCEND STUDY
• 70 Patient Prospective, Randomized, Blinded, Multi-Center Trial
• Target Commencement Q119, Completion by end 2019
The ASCEND Drug Coated Balloon is investigational is not currently available for sale in the United States.
20
The implants are limited by federal (or United States) law to investigational use only.
Emerging Opportunity Outside the US
21
NASDAQ: XENT